Chemical Biology and Drug Design

APRIL 15, 2023

The chemosensitive effects of miR-34 is mediated through increasing DNA damage and apoptosis in a p53 depended manner. The present study aimed to evaluate the effects of miR-34 restoration in OECM-1 oral cancer resistant to paclitaxel (OECM-1/PTX) and its underlying mechanisms through p53-mediated DNA damage and apoptosis.

DNA 100

DNA Protein Expression Research 100

Drug Target Review

JANUARY 26, 2024

To find a DNA fragment that contained the intact ACE2 gene, complete with its embedded regulatory information, they searched libraries of cloned DNA fragments generated as part of the Human Genome Project. Several of the mouse cell clones produced about 50 times more ACE2 than is normally present on mouse cells.

Production 114

Production DNA Virus Protein Expression 114

Broad Institute

OCTOBER 4, 2023

Related links Merkin Prize Inaugural Merkin Prize in Biomedical Technology awarded to Dr. Marvin Caruthers for developing technology that efficiently synthesizes DNA The inaugural Richard N. Caruthers was announced as the winner in June for his development, in 1981, of an efficient, automated technology for synthesizing DNA.

DNA 52

DNA RNA Science Protein Expression 52

DrugBank

JULY 24, 2024

Additionally, while small molecules can target well-defined pockets on enzymes or receptors, targeting PPIs presents a unique challenge due to their flat, featureless interfaces and large interaction areas. Despite these challenges, the progress in PPI-modulating drugs is noteworthy.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Drug Target Review

MAY 22, 2024

What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context. DNA vectors in mouse models?

Therapies 59

Therapies RNA Protein Expression DNA 59

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. For example, advances in media and feeds have contributed to higher cell protein expression by optimising nutrient availability and reducing accumulation of waste products within a culture.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

Alta Sciences

APRIL 17, 2024

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52